Skip to main content

CORRECTION article

Front. Oncol., 22 October 2024
Sec. Pediatric Oncology
Volume 14 - 2024 | https://doi.org/10.3389/fonc.2024.1487777

Corrigendum: Diagnosis and management of neurofibromatosis type 1 in Arabian Gulf Cooperation Council Region: challenges and recommendations

This article is a correction to:

  1. Diagnosis and management of neurofibromatosis type 1 in Arabian Gulf Cooperation Council Region: challenges and recommendations

    1. Read original article
Fahad A. Bashiri*&#x;Fahad A. Bashiri1*†Khaled Hundallah&#x;Khaled Hundallah2†Musaad Abukhaled&#x;Musaad Abukhaled3†Mossaed Mohammed Alyahya&#x;Mossaed Mohammed Alyahya4†Amna Al Futaisi&#x;Amna Al Futaisi5†Daniah Alshowaeir&#x;Daniah Alshowaeir6†Asmaa Al Tawari&#x;Asmaa Al Tawari7†Shaker Abdullah&#x;Shaker Abdullah8†Ata Ur Rehman Maaz&#x;Ata Ur Rehman Maaz9†Eman Taryam AlShamsi&#x;Eman Taryam AlShamsi10†Walaa Alshuaibi&#x;Walaa Alshuaibi11†Faisal Alotaibi&#x;Faisal Alotaibi12†Hesham Aldhalaan&#x;Hesham Aldhalaan13†
  • 1Division of Pediatric Neurology, Department of Pediatrics, College of Medicine, King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia
  • 2Prince Sultan Military Medical City, Riyadh, Saudi Arabia
  • 3Neuroscience Centre, King Faisal Specialist Hospital and Research Centre, College of Medicine, Al Faisal University, Riyadh, Saudi Arabia
  • 4Consultant of Neuro-oncology and Neuromuscular-neurology, Department of Oncology, King Faisal Specialist Hospital and Research Centre, Department of Neuroscience, King Faisal Specialist Hospital and Research Centre, Al Faisal University, Riyadh, Saudi Arabia
  • 5Sultan Qaboos University, College of Medicine and Health Sciences, Muscat, Oman
  • 6Department of Ophthalmology, College of Medicine, King Saud University, Riyadh, Saudi Arabia
  • 7Pediatric Neurology Unit, Pediatric Department, AlSabah Hospital, Ministry of Health, Kuwait City, Kuwait
  • 8Department of Oncology, King Faisal Specialist Hospital & Research Center – Jeddah (KFSHRC-Jed), Jeddah, Saudi Arabia
  • 9HemOnc Division, Department of Child Health, Sidra Medicine, Doha, Qatar
  • 10Pediatric Hematology-Oncology Department, Al Jalila children’s specialty Hospital, Dubai, United Arab Emirates
  • 11Division of Medical Genetics, Department of Pediatrics, King Khalid University Hospital, College of Medicine, King Saud University, Riyadh, Saudi Arabia
  • 12Neuroscience Centre, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
  • 13Department of Neurosciences, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia

A Corrigendum on
Diagnosis and management of neurofibromatosis type 1 in Arabian Gulf Cooperation Council Region: challenges and recommendations

By Bashiri FA, Hundallah K, Abukhaled M, Alyahya MM, Al Futaisi A, Alshowaeir D, Al Tawari A, Abdullah S, Maaz AUR, AlShamsi ET, Alshuaibi W, Alotaibi F and Aldhalaan H (2024) Front. Oncol. 14:1323176. doi: 10.3389/fonc.2024.1323176

In the published article, there was an error in the FDA approval status of mirdametinib.

A correction has been made to section 6.4 Treatment of NF1, subsection 6.4.4 Targeted therapies, paragraph 1. This sentence previously stated:

“Mirdametinib is a recently approved MEK inhibitor in July 2023 for the management of NF1-associated plexiform neurofibromas (105).”

The corrected sentence appears below:

“Other MEK inhibitors, mirdametinib, binimetinib, and trametinib are being investigated for the treatment of NF1-associated plexiform neurofibromas (104, 105).”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: children, Gulf Cooperation Council, management, neurofibromatosis type 1, referral

Citation: Bashiri FA, Hundallah K, Abukhaled M, Alyahya MM, Al Futaisi A, Alshowaeir D, Al Tawari A, Abdullah S, Maaz AUR, AlShamsi ET, Alshuaibi W, Alotaibi F and Aldhalaan H (2024) Corrigendum: Diagnosis and management of neurofibromatosis type 1 in Arabian Gulf Cooperation Council Region: challenges and recommendations. Front. Oncol. 14:1487777. doi: 10.3389/fonc.2024.1487777

Received: 28 August 2024; Accepted: 27 September 2024;
Published: 22 October 2024.

Edited and Reviewed by:

Tang-Her Jaing, Chang Gung Children’s Hospital, Taiwan

Copyright © 2024 Bashiri, Hundallah, Abukhaled, Alyahya, Al Futaisi, Alshowaeir, Al Tawari, Abdullah, Maaz, AlShamsi, Alshuaibi, Alotaibi and Aldhalaan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Fahad A. Bashiri, fbashiri@ksu.edu.sa

†ORCID: Fahad A. Bashiri, orcid.org/0000-0003-1436-6727
Khaled Hundallah, orcid.org/0000-0003-2570-8462
Musaad Abukhaled, orcid.org/0009-0003-3539-1144
Mossaed Mohammed Alyahya, orcid.org/0000-0003-0938-6192
Amna Al Futaisi, orcid.org/0000-0002-8035-0849
Daniah Alshowaeir, orcid.org/0000-0001-5144-4056
Asmaa Al Tawari, orcid.org/0000-0003-1706-8848
Shaker Abdullah, orcid.org/0009-0001-3955-1032
Ata Ur Rehman Maaz, orcid.org/0000-0003-1399-5994
Eman Taryam AlShamsi, orcid.org/0000-0002-5580-8723
Walaa Alshuaibi, orcid.org/0000-0002-5571-8971
Faisal Alotaibi, orcid.org/0000-0002-5871-2209
Hesham Aldhalaan, orcid.org/0000-0001-7288-8588

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.